insinyur perlakuan kanker Pioneering sistem imun tarung panyakit

Pioneering cancer treatment engineers immune systems to fight disease

 

Powered by Guardian.co.ukArtikel ieu judulna “insinyur perlakuan kanker Pioneering sistem imun tarung panyakit” ieu ditulis ku Haroon Siddique, pikeun theguardian.com Rebo 9 Désémber 2015 14.50 UTC

Pasén jeung sirah jeung kanker beuheung nu narima perlakuan anyar groundbreaking nu ngawengku nyababkeun sistim imun maranéhanana ngarangna kasakit.

sidang, di Institute Nasional pikeun Research Kaséhatan puseur panalungtikan Kalautan di Guy jeung St Thomas 'NHS yayasan kapercayaan jeung Raja sacara College London, ngawengku sél getih bodas modifying genetik penderita 'ngarah ngakuan jeung narajang tumor nu.

sél getih bodas sistim imun nu alami dilengkepan pikeun ngaleungitkeun sél - leuwih utamana kainféksi - nu teu aya, tapi sakapeung kudu bantuan pikeun mikawanoh jeung sél kanker serangan.

Ngagunakeun sampel getih, tim BRC ieu nyampurkeun sél getih bodas di laboratorium jeung virus bahya nu nawarkeun dua gén anyar. Nu gene kahiji ngajadikeun eta gampang tumuwuh sél salila waktu maranéhanana di laboratorium bari kadua nyandak sél getih bodas pikeun mikawanoh jeung narajang tumor nu.

Principal investigator Dr John maher ceuk: "Dina kalolobaan kangker, metastasis, sumebarna panyakit ti bagian awak mana mimiti sejen teu nyambung langsung, nyaéta ngabalukarkeun commonest maot. Tapi, sirah jeung kanker beuheung anu mahiwal di nu sumebar lokal atawa kanceuh tina akun panyakit pikeun kalolobaan sangsara jeung pati. Ieu ngandung harti yén tumor bisa jadi inoperable jeung teu ngaleutikan di response ka perlakuan tradisional saperti kémoterapi atawa radiotherapy. "

perlakuan disebut a CAR T-cell and takes two weeks to produce. To maximise its safety and effectiveness the team is injecting the CAR T-cells directly into the tumour. CAR T-cell treatment has proven effective in some forms of leukaemia but the hope is that it can be developed further to benefit patients with so-called “solid cancers”, which form a discrete tumour mass, such as head and neck cancer.

Maher said success could have “significant implications for other solid cancers, especially those that spread within a natural space in the body, such as ovarian cancer (lining of the abdomen) or mesothelioma (lining of the lungs). In that setting, it may be possible to inject the CAR T-cells from the patient directly into the cavity, to localise the treatment where it is needed most”.

During the phase 1 trial, which aims to test the treatment’s safety and effectiveness, patients enrolled in groups will successively receive a higher number of cells to establish safe dosage, provided it does not produce significant side-effects. If it is successful, the treatment will need to be tested in larger numbers of patients to establish how effective it is at combating the cancer.

Dr Stephen Caddick, director of innovations at the Wellcome Trust, which co-funded the trial, ceuk: “By precision engineering immune cells to recognise and destroy tumours, researchers are hopeful that they will be able to improve the prospects for patients who have, until now, faced very limited treatment options.”

guardian.co.uk © wali News & Media Limited 2010

19630 0